Page last updated: 2024-11-05
vigabatrin and Infant, Newborn, Diseases
vigabatrin has been researched along with Infant, Newborn, Diseases in 1 studies
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
Research Excerpts
Excerpt | Relevance | Reference |
"We present a patient with early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome) with an excellent response to chloral hydrate to draw attention to a possible role of the "old" drug in the treatment of intractable epilepsy." | 7.71 | Successful treatment of Ohtahara syndrome with chloral hydrate. ( Komárek, V; Krsek, P; Maulisová, A; Procházka, T; Sebronová, V, 2002) |
"We present a patient with early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome) with an excellent response to chloral hydrate to draw attention to a possible role of the "old" drug in the treatment of intractable epilepsy." | 3.71 | Successful treatment of Ohtahara syndrome with chloral hydrate. ( Komárek, V; Krsek, P; Maulisová, A; Procházka, T; Sebronová, V, 2002) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Krsek, P | 1 |
Sebronová, V | 1 |
Procházka, T | 1 |
Maulisová, A | 1 |
Komárek, V | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression[NCT00865514] | | 2 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Difficulty in obtaining the solution from the compounding pharmacies caused a two year delay in start-up; the funding ended prior to study completion.) |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
1 other study available for vigabatrin and Infant, Newborn, Diseases